NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=125763&from=4 CLASS PERIOD: December 12, 2023 t ...

Merger Details - ESSA Bancorp Inc (Nasdaq: ESSA) is proposed to merge with CNB Financial Corporation under an agreement where ESSA shareholders will receive 0.8547 shares of CNB common stock for each outstanding share of ESSA common stock [1] Law Firm Background - Monteverde & Associates PC is a national class action securities firm headquartered in the Empire State Building, New York City, with a successful track record in trial and appellate courts, including the US Supreme Court [2] - The firm has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report [1][2] Investigation Information - Monteverde & Associates PC is investigating ESSA Bancorp Inc regarding the proposed merger with CNB Financial Corporation [1] - Shareholders with concerns or seeking additional information can contact the firm through their website or directly via email or telephone [3]

CLEARFIELD, PA and STROUDSBURG, PA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- CNB Financial Corporation (Nasdaq: CCNE) (“CNB”), parent company of CNB Bank, and ESSA Bancorp, Inc. (Nasdaq: ESSA) (“ESSA”), parent company of ESSA Bank & Trust (“ESSA Bank”), jointly announced today that they have entered into a definitive agreement pursuant to which ESSA will merge with and into CNB, and ESSA Bank will merge with and into CNB Bank. The combined company is expected to have approximately $8 billion in total assets, $7 bi ...

SECURITIES AND EXCHANGE COMMISSION 100 F Street NE Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended September 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-33384 ESSA Bancorp, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 20-8023072 (State or other jurisdiction of incorpor ...

Core Insights - ESSA Pharma Inc. has decided to terminate the Phase 2 clinical trial evaluating masofaniten combined with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) due to insufficient efficacy signals [1][2] - The interim analysis indicated that the enzalutamide monotherapy performed better than the combination treatment, leading to the conclusion that the primary endpoint of the study is unlikely to be met [1][2] - The company will also terminate other clinical studies involving masofaniten and will withdraw IND and CTAs in various regions, focusing on maximizing shareholder value [1][2] Company Overview - ESSA Pharma Inc. is a clinical-stage pharmaceutical company dedicated to developing novel therapies for prostate cancer [8] - The company retains all rights to masofaniten worldwide, which has received Fast Track designation from the FDA for treating mCRPC resistant to standard treatments [7] Clinical Trial Details - The Phase 2 study was designed as a randomized, open-label trial with a planned enrollment of 120 patients, but only 52 patients were included in the interim analysis [2][6] - The primary endpoint was the proportion of patients achieving a PSA90 response, with secondary endpoints including PSA50 response rates [3][4] Financial Position - As of September 30, 2024, ESSA had cash reserves and short-term investments totaling $126.8 million, with net working capital of $124.3 million [5] - The company has no long-term debt, indicating a strong liquidity position [5]

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. After 15.2 months of follow up, median time to PSA progression and radiographic progression free surv ...

Company Announcement - ESSA Pharma Inc. will present at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 9:10 a.m. ET in New York, NY [1] - The presentation will feature a fireside chat with key executives including David R. Parkinson, Peter Virsik, and David S. Wood [2] Company Overview - ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies specifically for the treatment of prostate cancer [3]

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected ...

Financial Performance - Total yield on average interest earning assets increased to 5.02% for the quarter ended June 30, 2024, from 4.60% for the quarter ended June 30, 2023[1]. - Total interest income increased to $77.4 million for the nine months ended June 30, 2024, compared with $60.4 million a year earlier[7]. - Total interest income increased by 17.9% to $25.7 million for the three months ended June 30, 2024, compared to $21.8 million for the same period in 2023[27]. - Net interest income before provision for credit losses was $14.2 million for the third quarter of 2024, down from $15.2 million in the third quarter of 2023[29]. - The Company's return on average assets for the three months ended June 30, 2024, was 0.72%, down from 0.88% for the same period in 2023[37]. - Noninterest income for the third quarter of 2024 was $2.1 million, an increase from $1.9 million a year earlier[39]. - Noninterest income for the nine months ended June 30, 2024, was $6.1 million, compared to $5.9 million a year earlier[40]. Interest Expenses and Liabilities - Total cost of interest-bearing liabilities increased to 2.80% for the quarter ended June 30, 2024, from 1.75% for the quarter ended June 30, 2023[2]. - Total interest expense rose by 76.3% to $11.5 million for the three months ended June 30, 2024, compared to $6.5 million for the same period in 2023[28]. Credit Losses and Asset Quality - The provision for credit losses for the three months ended June 30, 2024, was a release of $347,000 compared to a provision of $150,000 for the same period in 2023[3]. - The provision for credit losses decreased by $497,000 for the third quarter of fiscal 2024 compared to the same quarter of 2023[37]. - Provision for credit losses decreased by $1.7 million for the nine months ended June 30, 2024, compared to the same period in 2023[38]. - The allowance for credit losses to total loans was 0.89% at June 30, 2024, down from 1.09% at September 30, 2023[31]. - The ratio of nonperforming assets to total assets was 0.56% at June 30, 2024, compared to 0.63% at September 30, 2023[31]. - Nonperforming assets were $12.4 million, or 0.56% of total assets at June 30, 2024, down from $14.4 million or 0.63% at September 30, 2023[45]. Loans and Deposits - Lending activity showed a 3.1% growth in commercial real estate loans to $847.6 million at June 30, 2024, from $822.0 million at September 30, 2023[4]. - Total net loans increased to $1.71 billion at June 30, 2024, from $1.68 billion at September 30, 2023[30]. - Residential real estate loans were $713.4 million at June 30, 2024, compared to $713.3 million at September 30, 2023[43]. - Consumer loans increased to $50.0 million at June 30, 2024, from $48.2 million at September 30, 2023[44]. - Total deposits were $1.55 billion at June 30, 2024, down from $1.66 billion at September 30, 2023, with core deposits comprising 64% of total deposits[5]. - Noninterest bearing demand accounts decreased by 7% to $261.3 million at June 30, 2024, from September 30, 2023[9]. Capital and Equity - The Bank maintained a Tier 1 capital ratio of 9.8% at June 30, 2024, exceeding regulatory standards[10]. - The Tier 1 capital ratio was 9.8% at June 30, 2024, indicating strong financial strength[32]. - Total stockholders' equity increased to $225.5 million at June 30, 2024, from $219.7 million at September 30, 2023[10]. - Tangible book value per share increased to $20.89 at June 30, 2024, from $19.80 at September 30, 2023[6]. Assets - Total assets were $2.2 billion at June 30, 2024, a decrease of $59.6 million, or 2.6%, from $2.3 billion at September 30, 2023[42].

Company Performance - Essa Bancorp reported revenues of $16.28 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 5.82% and down from $17.18 million year-over-year [1] - The company posted quarterly earnings of $0.41 per share, which was below the Zacks Consensus Estimate of $0.45 per share and compared to earnings of $0.45 per share a year ago [8] - The earnings surprise for the quarter was -8.89%, while a quarter ago, the bank had a positive surprise of 37.14% with actual earnings of $0.48 per share against an expectation of $0.35 [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $17.07 million, and for the current fiscal year, it is $1.80 on revenues of $68.04 million [12] - The estimate revisions trend for Essa Bancorp is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [5] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [9] Industry Context - The Financial - Savings and Loan industry, to which Essa Bancorp belongs, is currently in the bottom 27% of over 250 Zacks industries, which may impact stock performance [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly affect Essa Bancorp's stock [11]